AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Myriad Genetics (MYGN) shares fell 1.88% today, reaching their lowest level since September 1998, with an intraday decline of 2.15%.
Guggenheim recently downgraded
from a "buy" rating to a "neutral" rating in a research report released on April 11, 2025. This change in rating is likely to have contributed to the recent decline in the company's stock price. The downgrade suggests that analysts at Guggenheim may have concerns about the company's future prospects or its ability to meet market expectations.
Knowing stock market today at a glance

Dec.24 2025

Dec.24 2025

Dec.24 2025

Dec.24 2025

Dec.24 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet